Search Results

Return to List
Results 1–9 of 9
Title Date
1.

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2014)

ABSTRACT: Aromatase inhibitors appear to be effective as an adjuvant treatment for early-stage and late-stage breast cancer. Their role in chemoprevention of breast cancer in high-risk patients remains to be defined. Side effects of aromatase inhibitors in postmenopausal women are due to estrogen-...

August 2008

PDF Format
2.

Gynecologic Concerns in Children and Adolescents With Cancer

Number 607

ABSTRACT: Advancements in radiation therapy, chemotherapy, surgery, and multimodal treatment have dramatically improved childhood cancer survival. However, cancer and its treatment may have immediate or delayed adverse effects on reproductive health. Gynecologists should be prepared to manage gyne...

August 2014

PDF Format
3.

Human Papillomavirus Vaccination

Number 588

(Replaces Committee Opinion Number 467, September 2010)

ABSTRACT: The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that human papillomavirus (HPV) vaccination routinely be targeted to females and males aged 11 years or 12 years as part of the adolescent immunization platform to help reduce th...

March 2014

PDF Format
4.

Management of Vulvar Intraepithelial Neoplasia

Number 509

(Reaffirmed 2014)

ABSTRACT: Vulvar intraepithelial neoplasia (VIN) is an increasingly common problem, particularly among women in their 40s. The term VIN is used to denote high-grade squamous lesions and is subdivided into usual-type VIN (including warty, basaloid, and mixed VIN) and differentiated VIN. Usual-type ...

November 2011

PDF Format
5.

Oocyte Cryopreservation

Number 584

ABSTRACT: In 2013, the American Society for Reproductive Medicine and the Society for Assisted Repro-ductive Technology published a joint document, Mature Oocyte Cryopreservation: A Guideline, which addresses advances in techniques to freeze human eggs that have resulted in significant recent impr...

January 2014

PDF Format
6.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT: Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding, and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding eme...

August 2014

PDF Format
7.

Salpingectomy for Ovarian Cancer Prevention

Number 620

ABSTRACT: Ovarian cancer has the highest mortality rate out of all types of gynecologic cancer and is the fifth leading cause of cancer deaths among women. Current attempts at screening for ovarian cancer have been unsuccessful and are associated with false-positive test results that lead to unnec...

January 2015

PDF Format
8.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT: Tamoxifen, a nonsteroidal antiestrogen agent, is widely used as adjunctive therapy for women with breast cancer, and it has been approved by the U.S. Food and Drug Administration for adjuvant treatment of breast cancer, treatment of metastatic breast cancer, and reduction in breast cance...

June 2014

PDF Format
9.

The Role of the Obstetrician Gynecologist in the Early Detection of Epithelial Ovarian Cancer

Number 477

(Replaces No. 280, December 2002)

ABSTRACT: Epithelial ovarian cancer is most commonly detected in an advanced stage, when the overall 5-year survival rate is 20–30%. Detection of early-stage ovarian cancer results in improved survival. Currently, there is no effective strategy for ovarian cancer screening. Women with persistent a...

March 2011

PDF Format